Related references
Note: Only part of the references are listed.Fc Engineering to Improve the Function of Therapeutic Antibodies
Futa Mimoto et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2016)
Half-life extended biotherapeutics
Roland E. Kontermann
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Christian Klein et al.
MABS (2016)
A comprehensive review of the neonatal Fc receptor and its application in drug delivery
Joao Pedro Martins et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Coming-of-Age of Antibodies in Cancer Therapeutics
B. Vijayalakshmi Ayyar et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
Algirdas Grevys et al.
JOURNAL OF IMMUNOLOGY (2015)
The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies
Amita Datta-Mannan et al.
MABS (2015)
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics
Amita Datta-Mannan et al.
MABS (2015)
The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity
Yasmina Noubia Abdiche et al.
MABS (2015)
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Colby A. Souders et al.
MABS (2015)
Unraveling the interaction between FcRn and albumin: opportunities for design of albumin-based therapeutics
Kine Marita Knudsen Sand et al.
FRONTIERS IN IMMUNOLOGY (2015)
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge
Bing Li et al.
MABS (2014)
A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
Gabriel J. Robbie et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Craig Giragossian et al.
CURRENT DRUG METABOLISM (2013)
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Tilman Schlothauer et al.
MABS (2013)
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Narendra Chirmule et al.
AAPS JOURNAL (2012)
A strategy for risk mitigation of antibodies with fast clearance
Isidro Hoetzel et al.
MABS (2012)
FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys
Amita Datta-Mannan et al.
DRUG METABOLISM AND DISPOSITION (2012)
Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies Retrospective Analysis of Monkey as a Single Species for First-in-Human Prediction
Jennifer Q. Dong et al.
CLINICAL PHARMACOKINETICS (2011)
Neonatal Fc receptor and IgG-based therapeutics
Timothy T. Kuo et al.
MABS (2011)
Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data What have we learned?
Rong Deng et al.
MABS (2011)
Engineering the variable region of therapeutic IgG antibodies
Tomoyuki Igawa et al.
MABS (2011)
Antibody fragments Hope and hype
Aaron L. Nelson
MABS (2010)
Reduced elimination of IgG antibodies by engineering the variable region
T. Igawa et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Strategies and challenges for the next generation of therapeutic antibodies
Alain Beck et al.
NATURE REVIEWS IMMUNOLOGY (2010)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies
Carlos Vaccaro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Ligand valency affects transcytosis, recycling and intracellular trafficking mediated by the neonatal Fc receptor
Devin B. Tesar et al.
TRAFFIC (2006)
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life
B Gurbaxani et al.
MOLECULAR IMMUNOLOGY (2006)
Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies
RJ Ober et al.
INTERNATIONAL IMMUNOLOGY (2001)
Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex:: Mechanism of pH-dependent binding
WL Martin et al.
MOLECULAR CELL (2001)
Share Paper
